Cor Vasa 2012, 54(11-12):e421-e427 | DOI: 10.1016/j.crvasa.2012.11.003

Quality of life and costs of conventional therapy in patients treated by catheter ablation for atrial fibrillation

Veronika Bulkováa,b,*, Martin Fialac, Dan Wichterlea, Luděk Hamand, Jan Chovančíkc, Štěpán Havráneka, Jiří Dudad, Jakub Pindorc, Miroslav Novákb, Petr Pařízekd
a II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha, Česká republika
b International Clinical Research Center - I. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně, Brno, Česká republika
c Oddělení kardiologie, Kardiocentrum, Nemocnice Podlesí, a. s., Třinec, Česká republika
d I. interní kardioangiologická klinika, Lékařská fakulta Univerzity Karlovy v Hradci Králové a Fakultní nemocnice Hradec Králové, Hradec Králové, Česká republika

Aims: The purpose of the study was to assess quality of life, socioeconomic parameters, and costs of conventional therapy in patients treated by catheter ablation for atrial fibrillation (AF).

Methods: The study included 160 patients treated by catheter ablation for AF who fulfilled a minimum of 2-year follow-up. Quality of life using EQ-5D questionnaire, and days of hospitalization and working incapacity were evaluated before ablation and every 6 months after ablation. Further, one-year costs of conventional therapy for AF were assessed before and after ablation.

Results: Quality of life was significantly improved at each post-ablation stage. EQ-5D index increased from baseline 68 ± 14 to 76 ± 17 after 2 years (p < 0.001), and EQ-VAS score from baseline 65 ± 17 to 71 ± 15 after 2 years (p = 0.01). Significant reduction was further observed in the count of hospitalization days and days of working incapacity (both p < 0.01). The cost of conventional therapy per patient per year decreased from 49,337 Czech crowns (1974 €) before ablation to 16,504 CZC (660 €) and 13,576 CZC (543 €) in the first and second post-ablation year, respectively.

Conclusion: AF ablation was associated with significant improvement in quality of life, and decrease in days of hospitalization and working incapacity. There was more than three-fold reduction in the costs of conventional therapy observed in the first two years after ablation.

Keywords: Atrial fibrillation; Catheter ablation; Conventional therapy; Costs of therapy; Quality of life

Received: September 25, 2012; Revised: November 6, 2012; Accepted: November 7, 2012; Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bulková V, Fiala M, Wichterle D, Haman L, Chovančík J, Havránek Š, et al.. Quality of life and costs of conventional therapy in patients treated by catheter ablation for atrial fibrillation. Cor Vasa. 2012;54(11-12):e421-427. doi: 10.1016/j.crvasa.2012.11.003.
Download citation

References

  1. T.S. Tsang, G.W. Petty, M.E. Barnes, et al., The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades, Journal of the American College of Cardiology 42 (2003) 93-100. Go to original source... Go to PubMed...
  2. Y. Miyasaka, M.E. Barnes, B.J. Gersh, et al., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence, Circulation 114 (2006) 119-125. Go to original source... Go to PubMed...
  3. W. Greiner, T. Weijnen, M. Nieuwenhuizen, et al., A single European currency for EQ-5D health states. Results from a six country study, European Journal of Health Economics 4 (2003) 222-231. Go to original source... Go to PubMed...
  4. R. Cappato, H. Calkins, S.A. Chen, et al., Worldwide survey on the methods. Efficacy, and safety of catheter ablation for human atrial fibrillation, Circulation 111 (2005) 1100-1105. Go to original source... Go to PubMed...
  5. R. Cappato, H. Calkins, S.A. Chen, et al., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation, Circulation 3 (2010) 32-38. Go to original source... Go to PubMed...
  6. C. Pappone, S. Rosanio, G. Augello, et al., Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study, Journal of the American College of Cardiology 42 (2003) 185-197. Go to original source... Go to PubMed...
  7. O.M. Wazni, N.F. Marrouche, D.O. Martin, et al., Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial, The Journal of the American Medical Association 293 (2005) 2634-2640. Go to original source... Go to PubMed...
  8. P. Jais, B. Cauchemez, L. Macle, et. al., Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study, Circulation 118 (2008) 2498-2505. Go to original source... Go to PubMed...
  9. D.J. Wilber, C. Pappone, P. Neuzil, et al., Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial, The Journal of the American Medical Association 303 (2010) 333-340. Go to original source... Go to PubMed...
  10. A. Wokhlu, K.H. Monahan, D.O. Hodge, et al., Long-term quality of life after ablation of atrial fibrillation: the impact of recurrence symptom relief, and placebo effect, Journal of the American College of Cardiology 55 (2010) 2309-2316. Go to original source... Go to PubMed...
  11. C. Pappone, G. Vicedomini, G. Augello, et al., Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: The APAF Study, Circulation. Arrhythmia and Electrophysiology 4 (2011) 808-814. Go to original source... Go to PubMed...
  12. V. Bulková, M. Fiala, J. Chovančík, et al., Analýza nákladů na léčbu u pacientů s fibrilací síní v České republice, Cor et Vasa 50 (2008) 23-27. Go to original source...
  13. J.Y. Le Heuzey, O. Paziaud, O. Piot, et al., Cost of care distribution in atrial fibrillation patients: the COCAF study, American Heart Journal 147 (2004) 121-126. Go to original source... Go to PubMed...
  14. K. Moeremans, E. Aliot, C. Chillou, et al., Second line pharmacological management of paroxysmal and persistent atrial fibrillation in France: a cost analysis, Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 6 (2000) 407-416. Go to original source... Go to PubMed...
  15. L.F. Hsu, P. Jaïs, P. Sanders, et al., Catheter ablation for atrial fibrillation in congestive heart failure, The New England Journal of Medicine 351 (2004) 2373-2383. Go to original source... Go to PubMed...
  16. P.J. Gentlesk, W.H. Sauer, E.P. Gerstenfeld, et al., Reversal of left ventricular dysfunction following ablation of atrial fibrillation, Journal of Cardiovascular Electrophysiology 18 (2007) 9-14. Go to original source... Go to PubMed...
  17. P.S. Chan, S. Vijan, F. Morady, et al., Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation, Journal of the American College of Cardiology 47 (2006) 2513-2520. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.